Last reviewed · How we verify
Prednisolone acetate 1% ophthalmic suspension
Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators.
Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators. Used for Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, Steroid-responsive inflammatory conditions of the eye such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides.
At a glance
| Generic name | Prednisolone acetate 1% ophthalmic suspension |
|---|---|
| Sponsor | Carolina Eyecare Physicians, LLC |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Prednisolone acetate binds to glucocorticoid receptors in ocular tissues, leading to decreased synthesis of prostaglandins, leukotrienes, and other inflammatory mediators. This reduces infiltration of inflammatory cells, decreases vascular permeability, and suppresses both humoral and cell-mediated immune responses in the eye. The acetate ester formulation provides enhanced corneal penetration compared to other prednisolone formulations.
Approved indications
- Inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe
- Steroid-responsive inflammatory conditions of the eye such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Secondary ocular infection
- Ocular irritation or discomfort
- Blurred vision
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery (PHASE4)
- Pilocarpine Use After Kahook Goniotomy (PHASE3)
- A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (PHASE1)
- Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (PHASE4)
- Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population (PHASE3)
- A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: